Uroplasty publishes female incontinence trial data

USA-based Uroplasty has published positive results from a clinical study of its Macroplastique for the treatment of female stress urinary  incontinence in the Journal of Urology.

The multicenter, randomized trial compared the safety and efficacy of  Macroplastique to another bulking agent. In the active group, the  dry/cure rate was 37% versus 25% in the control group, with a 62%  improvement vs 48%, respectively.

"This study shows the clear benefits of Macroplastique, an injectable  soft tissue urethral bulking agent, bringing the majority of treated  patients either freedom from unwanted urinary leakage or fewer  episodes," said chief executive David Kaysen. "Some other  commercially-available bulking agents may be absorbed into the body,  potentially diminishing their clinical benefit. Macroplastique implants  are suspended in a water-soluble gel that, once removed from the body,  leaves behind the soft, flexible permanent elastomer implants that can  sustain the treatment's benefits and provide patients with an improved  outcome," he added.